Masimo (NASDAQ:MASI) updated its FY 2020
Pre-Market earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 3.56-3.56 for the period, compared to the Thomson Reuters consensus estimate of $3.56. The company issued revenue guidance of $1.035-1.035 billion, compared to the consensus revenue estimate of $1.04 billion.Masimo also updated its FY 2019
Pre-Market guidance to 3.18 EPS.
NASDAQ MASI traded down $3.04 during trading hours on Tuesday, hitting $161.96. 2,131 shares of the company’s stock traded hands, compared to its average volume of 302,750. Masimo has a 52-week low of $110.98 and a 52-week high of $165.48. The company has a market capitalization of $8.68 billion, a PE ratio of 53.28, a PEG ratio of 2.02 and a beta of 1.13. The firm’s 50-day moving average is $157.78 and its 200-day moving average is $151.93.
Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.03. Masimo had a net margin of 20.83% and a return on equity of 17.32%. The company had revenue of $229.01 million during the quarter, compared to analysts’ expectations of $221.92 million. During the same quarter in the prior year, the company earned $0.71 EPS. Masimo’s revenue was up 8.8% compared to the same quarter last year. On average, equities research analysts predict that Masimo will post 3.17 EPS for the current year.
MASI has been the topic of several recent analyst reports. BidaskClub upgraded shares of Masimo from a hold rating to a buy rating in a report on Monday, December 16th. Piper Jaffray Companies reiterated an overweight rating and issued a $175.00 target price (up from $161.00) on shares of Masimo in a report on Tuesday, December 17th. Finally, ValuEngine lowered shares of Masimo from a buy rating to a hold rating in a report on Wednesday, October 2nd. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Masimo has a consensus rating of Buy and a consensus target price of $161.75.
In other news, Director Sanford Fitch sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $147.08, for a total value of $956,020.00. Following the transaction, the director now directly owns 50,745 shares in the company, valued at approximately $7,463,574.60. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Bilal Muhsin sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $155.00, for a total transaction of $465,000.00. Over the last 90 days, insiders sold 56,000 shares of company stock worth $8,683,715. Company insiders own 11.50% of the company’s stock.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Read More: How to build a Fibonacci channel
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.